You are here:

talimogene laherparepvec (Imlygic)

Advice

in the absence of a submission from the holder of the marketing authorisation:

talimogene laherparepvec (Imlygic®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: talimogene laherparepvec (Imlygic)
SMC Drug ID: 1248/17
Manufacturer: Amgen Ltd
Indication: Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 May 2017

Back